RegCell Hires Michael McCullar as CEO

News
Article

Company’s new leader previously served in the same role at OnQuality Pharmaceuticals.

Immune system. A complex network of organs, cells and proteins that defends the body against infection, whilst AI Generated. Image Credit: Adobe Stock Images/Hadi

Image Credit: Adobe Stock Images/Hadi

RegCell, a biotech company, revealed that it has officially appointed Michael McCullar as CEO and representative director. Previously, he served as CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities.

"I am honored to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases," said McCullar. "In an era where the increasingly aging population is facing an escalating burden of autoimmune disorders, Treg-based cellular therapies are opening the doors to exciting new treatment possibilities. I look forward to contributing my expertise towards validating the promising potential of our regulatory T cell platform and expanding our U.S. footprint as we advance our programs towards the clinic in 2024."

Reference: RegCell Appoints Experienced Life Science Executive and Entrepreneur Michael McCullar, Ph.D., MBA, as its New Chief Executive Officer. PR Newswire. October 19, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/regcell-appoints-experienced-life-science-executive-and-entrepreneur-michael-mccullar-phd-mba-as-its-new-chief-executive-officer-301961646.html

Recent Videos
Fred Aslan
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Fred Aslan
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Fred Aslan
Related Content
Azurity Pharmaceuticals Completes Covis Pharma Acquisition

Azurity Pharmaceuticals Completes Covis Pharma Acquisition

Don Tracy, Associate Editor
March 14th 2025
Article

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics areas.

Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

High Impact

High Impact

Mike Hennessy Jr.
March 14th 2025
Article

As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Stock.adobe.com

Corporate Versus Tradition: A Discussion on Venture Innovation

Mike Hollan
March 14th 2025
Article

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in pharma investing.

Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment

Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment

Don Tracy, Associate Editor
March 14th 2025
Article

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.